These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 15577131

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ, Craig Jordan V.
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [Abstract] [Full Text] [Related]

  • 3. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO, U.S. Preventive Services Task Force.
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract] [Full Text] [Related]

  • 4. [Effects of raloxifene on other organs without bone: uterus].
    Nozaki M.
    Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
    [Abstract] [Full Text] [Related]

  • 5. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Oct; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 6. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR.
    Int J Fertil Womens Med; 1999 Oct; 44(5):221-6. PubMed ID: 10569450
    [Abstract] [Full Text] [Related]

  • 7. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W, Netelenbos JC.
    Ned Tijdschr Geneeskd; 1999 Aug 28; 143(35):1771-6. PubMed ID: 10494328
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL, Cheng MH, Chao HT, Wang PH.
    Taiwan J Obstet Gynecol; 2008 Mar 28; 47(1):24-31. PubMed ID: 18400579
    [Abstract] [Full Text] [Related]

  • 10. Chemoprevention of breast cancer.
    O'Regan RM.
    Cancer Treat Res; 2000 Mar 28; 103():183-207. PubMed ID: 10948447
    [No Abstract] [Full Text] [Related]

  • 11. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV, Goldstein SR.
    Menopause; 2010 Mar 28; 17(3):642-53. PubMed ID: 20107426
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. SERMs: meeting the promise of multifunctional medicines.
    Jordan VC.
    J Natl Cancer Inst; 2007 Mar 07; 99(5):350-6. PubMed ID: 17341726
    [Abstract] [Full Text] [Related]

  • 14. [Selective estrogen receptor modulators (SERMs) in the practice].
    Nagykálnai T.
    Magy Onkol; 2002 Mar 07; 46(2):165-75. PubMed ID: 12202896
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
    Harv Womens Health Watch; 2002 Oct 07; 10(2):1-2. PubMed ID: 12393316
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
    Runowicz CD.
    Health News; 2003 Apr 07; 9(4):1-2. PubMed ID: 12710388
    [No Abstract] [Full Text] [Related]

  • 20. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May 08; 48(1234):37. PubMed ID: 16685245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.